{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T08:06:31Z","timestamp":1779782791610,"version":"3.53.1"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T00:00:00Z","timestamp":1770163200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2016909"],"award-info":[{"award-number":["2016909"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2025289"],"award-info":[{"award-number":["2025289"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","award":["2025894"],"award-info":[{"award-number":["2025894"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>To explore the practices, confidence and perspectives of community pharmacists in deprescribing high\u2010risk psychotropic medicines, including opioid analgesics, benzodiazepine, gabapentinoids and medicinal cannabis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An anonymous, cross\u2010sectional national online survey was conducted between January and April 2025 among Australian community pharmacists. The survey captured data on pharmacist demographics, their workplace (pharmacy) characteristics, their provision of high\u2010risk psychotropic medicines, and pharmacists' perspectives, confidence and practices related to implementing strategies to support deprescribing of these medicines. Descriptive statistics and logistic regression analyses were conducted to explore the factors associated with initiating discussions with patients about deprescribing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The sample comprised of 730 pharmacists, representing approximately 12% of all Australian community pharmacies. Approximately three\u2010quarters indicated their pharmacy received prescriptions every day for opioids (80.6%), benzodiazepines (75.2%) and gabapentinoids (72.1%), whilst fewer than one\u2010tenth of pharmacies (8.9%) received medicinal cannabis prescriptions every day. Pharmacists working outside of capital cities (i.e. other urban, rural or remote areas; adjusted odds ratio (aOR): 1.33, 95% confidence intervals (CIs): 0.97\u20131.83), pharmacy managers\/owners (aOR: 1.29, 95% CIs: 1.22\u20131.50) and those with \u2265 15\u2009years of professional experience (OR: 1.57, 95% CIs: 1.17\u20132.11) had higher odds of initiating discussions on deprescribing psychotropic medicines compared with those working in capital cities, employee pharmacists and those with &lt;15\u2009years of professional experience, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These findings provide some of the first insights into deprescribing practices of high\u2010risk psychotropic medicines within community pharmacy settings, highlighting clear opportunities to strengthen these practices, particularly through supporting early\u2010career pharmacists and those practicing in capital cities.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70466","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T13:43:35Z","timestamp":1770212615000},"page":"1911-1921","source":"Crossref","is-referenced-by-count":0,"title":["Community pharmacists' practices and perspectives on deprescribing high\u2010risk psychotropic medicines: National survey findings"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6458-1279","authenticated-orcid":false,"given":"Monica","family":"Jung","sequence":"first","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"Picco","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aili V.","family":"Langford","sequence":"additional","affiliation":[{"name":"Sydney Pharmacy School, Faculty of Medicine and Health The University of Sydney  Sydney New South Wales Australia"},{"name":"Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences Monash University  Parkville Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Laing","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Dostal","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5341-1055","authenticated-orcid":false,"given":"Suzanne","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Monash Addiction Research Centre, Eastern Health Clinical School Monash University  Melbourne Victoria Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,4]]},"reference":[{"key":"e_1_2_12_2_1","unstructured":"Australian Institute of Health and Welfare. Alcohol Tobacco & other drugs in Australia. Australian Government. Accessed September 5 2024.https:\/\/www.aihw.gov.au\/reports\/alcohol\/alcohol-tobacco-other-drugs-australia"},{"key":"e_1_2_12_3_1","unstructured":"World Health Organization.Medication Without Harm. Accessed October 12 2023.https:\/\/www.who.int\/initiatives\/medication-without-harm#:~:text=WHO%27s%20goal%20is%20to%20achieve in%20the%20next%205%20years"},{"key":"e_1_2_12_4_1","unstructured":"World Health Organization.Opioid overdose. Accessed May 12 2024.https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/opioid-overdose"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(19)32229\u20109"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2019.02.033"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010016\u20100397\u20108"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467\u2010023\u201040637\u20108"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12954\u2010022\u201000666\u2010w"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.11677"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.31128\/AJGP\u201004\u201021\u20105939"},{"key":"e_1_2_12_12_1","unstructured":"Therapeutic Goods Administration.Planned consultation to address growing safety concerns of unapproved medicinal cannabis products in Australia. Accessed August 11 2025.https:\/\/www.tga.gov.au\/news\/news\/planned-consultation-address-growing-safety-concerns-unapproved-medicinal-cannabis-products-australia#:~:text=This%20consultation%2C%20which%20will%20commence levels%20of%20tetrahydrocannabinol%20(THC)"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12913\u2010021\u201006056\u20105"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14525"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002746"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11606\u2010025\u201009499\u20102"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs\u20102020\u2010010881"},{"key":"e_1_2_12_18_1","unstructured":"Australian Government Department of Health DaA.National Medicines Policy. Accessed August 29 2025.https:\/\/www.health.gov.au\/resources\/publications\/national-medicines-policy"},{"key":"e_1_2_12_19_1","unstructured":"Australian Government Department of Health DaA.National Strategy for Quality Use of Medicines. Accessed August 29 2025.https:\/\/www.health.gov.au\/resources\/publications\/national-strategy-for-quality-use-of-medicines"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rcsop.2025.100625"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14947"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/17151635241246975"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.52002"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riab079"},{"key":"e_1_2_12_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy9020095"},{"key":"e_1_2_12_26_1","unstructured":"Australian Government Department of Health and Aged Care.National Drug Strategy 2017\u20132026. Accessed September 5 2024.https:\/\/www.health.gov.au\/resources\/publications\/national-drug-strategy-2017-2026"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.13517"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010024\u201001773\u20103"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2024.09.001"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.08.009"},{"key":"e_1_2_12_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103856"},{"key":"e_1_2_12_32_1","unstructured":"Monash University.Opioid Safety Toolkit. Accessed July 21 2025.https:\/\/saferopioiduse.com.au"},{"key":"e_1_2_12_33_1","volume-title":"Stata statistical software: release 18","author":"StataCorp","year":"2023"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/19315864.2025.2521323"},{"key":"e_1_2_12_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2025.03.002"},{"key":"e_1_2_12_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096\u2010022\u201001519\u2010z"},{"key":"e_1_2_12_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/ijpp\/riac005"},{"key":"e_1_2_12_38_1","doi-asserted-by":"publisher","DOI":"10.1159\/000515069"},{"key":"e_1_2_12_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00406\u2010024\u201001893\u2010x"},{"key":"e_1_2_12_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2023.107667"},{"key":"e_1_2_12_41_1","doi-asserted-by":"publisher","DOI":"10.7326\/M22\u20100217"},{"key":"e_1_2_12_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2020.102926"},{"key":"e_1_2_12_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000002340"},{"key":"e_1_2_12_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2020.02.009"},{"key":"e_1_2_12_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2015.05.008"},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2019.12.023"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1111\/dar.14009"},{"key":"e_1_2_12_48_1","unstructured":"Therapeutic Goods Administration.Pregabalin and gabapentin. Accessed September 2 2025.https:\/\/www.tga.gov.au\/safety\/about-market-actions\/product-alert-market-actions\/pregabalin-and-gabapentin"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmacy4030026"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102023\u2010081934"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2018.01.004"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70466","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70466","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70466","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,26]],"date-time":"2026-05-26T07:48:58Z","timestamp":1779781738000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,4]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/bcp.70466"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70466","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,4]]}}}